Sanofi is strengthening its vaccine business by acquiring an Austrian company. The French pharma group is taking over skin disease specialist Origrimm Biotechnology.
US cell & gene therapy manufacturer Orgenesis Inc. announced that its joint venture with Theracell Advanced Biotechnology SA has received €32m in funding by Enterprise Greece.
The start-up competition @AMR conference supported by INCATE has started. Early-stage ventures fighting drug resistant bacterial infections in the therapeutics or diagnostics area interested to be on stage are invited to apply now!
Quell Therapeutics has raised a whopping US$156m from a prestigious investor group in an oversubscribed Series B financing. With the funds, the British biotech wants to hasten its CAR-Treg cell therapy candidate on its way to the clinic.
Vaccibody rebrands as Nykode Therapeutics and teams up with Regeneron in a vaccine deal potentially worth US$925m.
The European Commission has inked the pre-purchase agreement over Valnevas inactivated whole virus pandemic vaccine VLA2001 announed in mid-October.
Swiss Vifor Pharma is shelling out more than €375m for Mallorca-based Sanifit, a clinical-stage cardio-renal biopharmaceutical company with a single compound in development.
Novo Nordisk announced today that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals for up to US$ 3.3bn, which is a surcharge of about 80%.
Pfizer Inc announced it will allow generic makers in 95 low income nations to produce and distribute its COVID-19 pill Paxlovid at cost price.
London-based Synthace, which develops software to automate biology experimentation, has raised US$35m in a Series C from notable investors.